For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Upadacitinib - Psoriatic arthritis
PAD Profile : Upadacitinib - Psoriatic arthritis
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Adalimumab
- Ciclosporin
- Etanercept
- Golimumab
- Infliximab
- Sulfasalazine
- Ustekinumab (Psoriasis)
- Certolizumab pegol
- Apremilast
- Secukinumab
- Ixekizumab
- Tofacitinib
- Methotrexate
- Guselkumab (Psoriasis)
- Risankizumab
Other Indications
- Rheumatoid arthritis
- Atopic dermatitis
- Non-radiographic axial spondyloarthritis
- Ankylosing spondylitis
- Inflammatory bowel disease
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated Psoriatic arthritis high cost immunomodulator treatment pathway.
The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends upadacitinib as a treatment option for the treatment of Psoriatic Arthritis in line with NICE TA768.
Upadacitinib will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA768.
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.